Efficacy of a pneumococcal conjugate vaccine against acute otitis media

New England Journal of Medicine

Volumn 344, Issue 6, 2001, Pages 403-409

  Eskola, Juhani ^a   Kilpi, Terhi ^a   Palmu, Arto ^a   Jokinen, Jukka ^a   Haapakoski, Jaason ^a   Herva, Elja ^a   Takala, Aino ^a   Käyhty, Helena ^a   Karma, Pekka ^b   Kohberger, Robert ^c   Siber, George ^c   Mäkelä, P Helena ^a   Lockhart, Stephen ^d   Eerola, Mervi ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c PFIZER INC   (United States)

^d Wyeth Lederle Vaccines   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ACUTE DISEASE; ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B VACCINES; HUMANS; INCIDENCE; INFANT; MALE; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0035825720     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200102083440602     Document Type: Article

References (39)

1. Otitis media in children
2. Otitis media in infancy and intellectual ability school achievement, speech, and language at age 7 years
3. Sequelae of recurrent acute otitis media: Ten-year follow-up of a prospectively studied cohort of children
4. Costs arising from otitis media
5. Cost-effectiveness considerations in otitis media treatment
6. Overall cost in the treatment of otitis media
7. Direct expenditures related to otitis media diagnoses: Extrapolations from a pediatric Medicaid cohort
8. Cefixime compared with amoxicillin for treatment of acute otitis media
9. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods
10. Ten-year review of otitis media pathogens
11. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media
12. Prevention of otitis media in children by pneumococcal vaccination
13. Sero-type distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for a conjugate vaccine
14. Pneumococcal serotypes from acute otitis media in rural Kentucky
15. Pneumococcal vaccine and otitis media
16. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston
17. Use of pneumococcal polysaccharide vaccine in preventing otitis media in infants: Different results between racial groups
18. Vaccination against Streptococcus pneumoniae in childhood: Lack of demonstrable benefit in young Australian children
19. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
20. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants
21. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
22. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
23. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants
24. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory
25. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid
26. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children
27. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugate to diphtheria or tetanus toxoid
28. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
29. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
30. Carriage of pneumococci after pneumococcal vaccination
31. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
32. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
33. Finnish approach to the treatment of acute otitis media: Report of the Finnish Consensus Conference
34. Detection of pneumococcal capsular polysaccharide antigens by latex agglutination, counterimmunoelectrophoresis, and radioimmunoassay in middle ear exudates in acute otitis media
35. Cox's regression model for counting processes: A large sample study
36. Repeatable events in life-history analysis; the effect of childhood separation on future mental health
37. Statistical methods in cancer research
38. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: Impact on pneumonia, otitis media, and an update on invasive disease - Results of the Northern California Kaiser Permanente Efficacy Trial